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Abstract Kawasaki disease (KD) is associated with the de-
velopment of coronary arterial lesions (CALs) in children. We
aimed to test the hypothesis that circulating 25-
hydroxyvitamin D3 [25-(OH)D3] could be identified as a
clinical parameter for predicting CALs secondary to KD in
children. We enrolled 35 children with KD in the acute phase
and measured serum 25-(OH)D3 levels in all of them, then
followed up by echocardiography for CALs. Additionally,
serum 25-(OH)D3 levels were obtained in 23 febrile children
with respiratory tract infections and 30 healthy children. Of
the 35 KD children, nine had CALs according to echocardi-
ography and 26 did not (NCALs). Serum 25-(OH)D3 levels
were not significantly different between NCALs and healthy
children (49.2±23.8 versus 44.1±30.2 ng/ml; P=0.49). Se-
rum 25-(OH)D3 levels were significantly higher in children
with CALs than those without CALs (83.9±26.3 versus 49.2
±23.8 ng/ml; P=0.001). The cutoff value of 65 ng/ml to
predict subsequent CALs had a specificity of 0.73, sensi-
t ivi ty of 0.78, and diagnostic accuracy of 0.74.
Conclusion: Serum 25-(OH)D3 levels were elevated dur-
ing the acute phase in KD children who had subsequent
CALs. Serum 25-(OH)D3 levels in the acute phase of KD
may be used to predict subsequent CALs.
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Introduction
Kawasaki disease (KD), first described in 1967 by Dr.
Tomisaku Kawasaki as mucocutaneous lymph node syn-
drome [7], is an acute systemic vasculitis that primarily affects
small- and medium-sized arteries. KD that predominantly
affects children younger than 5 years is mostly a self-
limiting disease, but sometimes gives rise to serious cardiac
complications. Coronary arterial lesions (CALs), including
dilatations and aneurysms, are identified as the most serious
complications of KD. In China, approximately 8.5 to 20.6 %
of KD patients develop CALs [4, 11, 12, 16, 28]. Even after
high-dose immunoglobulin therapy, 5–10 % of KD children
develop CALs [14]. CALs secondary to KD are associated
with changes in certain biomarkers, such as platelet count,
neutrophil count, plateletcrit, platelet distribution width, mean
platelet volume, erythrocyte sedimentation rate, cardiac tro-
ponin I, endothelin-1, albumin, and hemoglobin [3] . In a
retrospective study [2] involving 113 Chinese children,
Kobayashi scoring system was applied to predict coronary
arterial lesions in KD, and the results showed that the sensi-
tivity of the Kobayashi scoring system was 0.56. Though the
Kobayashi scoring system had the ability to predict the coro-
nary arterial lesions in KD patients, the power was not high
enough. Therefore, a laboratory marker in the initial acute
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stage of KD that could predict the development of subsequent
CALs is very much desired.
The exact mechanisms underlying the development of
CALs secondary to KD remain poorly understood. Several
markers of immune activation are increased in KD patients,
suggesting their involvement in the pathogenesis [8, 19, 27].
Hyperactive immune cells, especially T cells, with excessive
cytokines may be responsible for tissue injury in KD [10].
Either dietary vitamin D or that produced in the skin is
transported to the liver for conversion to 25-hydroxyvitamin
D3 [25-(OH)D3]. Circulating 25-(OH)D3 is the precursor of the
active 1,25-dihydroxyvitamin D3 (1,25-(OH)2D3). Almost ev-
ery tissue in the human body carries receptors for 1,25-(OH)2D3
(vitamin D receptor, VDR), which affects epithelial cell, T cell,
B cell, and dendritic cell functions. In addition, VDR has
been identified in the immune system [1, 5, 23, 25].
Adjunctive 1-alpha, 25-dihydroxyvitamin D3 therapy
exhibiting anti-inflammatory and immunomodulatory ef-
fects during KD vasculitis have been reported [9, 20]. The
expression of VDR in T cells was higher in KD patients
than febrile children with respiratory tract infections and
healthy children [17]. Over activated T cells might pro-
mote 25-(OH)D3 release. Therefore, more intense inflam
matory response in CALs’ patients may have increased
VDR expression and subsequently elevated 25-(OH)D3
levels. In addition, vitamin D deficiency as an indepen-
dent risk factor for arterial disease has been reported [22].
Taken together, we hypothesized that CALs induce exces-
sive vascular calcification; calcifications would stimulate
CYP27B1 enzyme expression and in turn increase serum
25-(OH)D3 levels. The purpose of this study was to investi-
gate the clinical value of serum 25-(OH) D3 levels as a
predictor of CALs in children with KD.
Material and methods
Study population
We enrolled 35 children diagnosed with KD [15] between
March 2011 and July 2013 at the Affiliated Hospital of Xi’an
Medical College. All the children received intravenous immune
globulin treatment. Once Kawasaki disease is diagnosed, im-
munoglobulin therapy should begin within 24 h. Echocardiog-
raphywas used to detect the presence of CALs during the course
of the disease. Of the 35 children diagnosed with KD, nine (six
boys and three girls) developed CALs based on echocardio-
graphic results and 26 (19 boys and 7 girls) did not develop
CALs (NCALs). In addition, 23 children with respiratory tract
infections were included as febrile controls. These children did
not have cutaneous eruption or myocardial injury and were
excluded if they had abnormal myocardial enzyme levels or an
abnormal electrocardiogram. Furthermore, 30 healthy children
were selected as normal controls. Children with heart, lung, or
kidney disease were excluded. The study was approved by the
Ethics Committee of the Affiliated Hospital of Xi’an Medical
College. Parental informed consent was obtained for each child
enrolled in this study. There were no significant differences
between the groups regarding baseline characteristics.
Measurement of serum 25-(OH)D3 levels
Fasting blood samples (approximately 3 ml) were collected
for each patient between 5 and 10 days of disease onset. The
samples were centrifuged at 3,000 rpm/min for 10 min and
stored at −70 °C until analysis. Serum 25-(OH)D3 concentra-
tions were measured using a commercially available ELISA
kit (Shanghai XinLe Biological Technology Co., Ltd.) accord-
ing to the manufacturer’s instructions. The same method was
used to measure 25-(OH) D3 levels in febrile children and
healthy control children.
Statistical analysis
Continuous data were expressed as mean±standard deviation
(SD) if the values were normally distributed. Statistical com-
parisons of continuous variables were performed by a two-
tailed Student’s t test. A χ2 test was used to compare categor-
ical variables. P<0.05 was considered statistically significant.
All analyses were performed with SPSS V.17.0 (SPSS Inc,
Chicago, Illinois, USA). To compare the power of serum level
of 25-(OH)D3 levels in predicting CALs, receiver-operating
characteristic curves (ROCs) were plotted and areas under the
curve (AUCs) were calculated
Results
The KD cases included 26 boys and 9 girls with an age range
of 4 months to 4 years. Six boys and three girls developed
CALs. The febrile children group included 11 boys and 12
girls with an age range of 5 months to 4 years. The normal
controls consisted of 16 boys and 14 girls with an age range of
5 months to 4 years.
Comparison of 25-(OH)D3 levels
The mean serum 25-(OH)D3 levels in febrile children was
significantly lower than healthy children (27.9±20.6 versus
44.1±30.2 ng/ml; P=0.025). This level was not significantly
different between NCALs and healthy children (49.2±23.8
versus 44.1±30.2 ng/ml; P=0.49) (Table 1). In addition, the
mean serum 25-(OH)D3 levels were significantly higher in
children with CALs than those without CALs (83.9±26.3
versus 49.2±23.8 ng/ml; P=0.001).
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ROCs
To assess the performance of serum level of 25-(OH)D3 in
predicting CALs, ROCs were plotted and the AUCs was
calculated. As shown in Fig. 1, the AUC for predicting CALs
of 25-(OH)D3 was 0.831. When the cutoff value of 65 ng/ml
for 25-(OH)D3 based on the ROC was obtained for predicting
CALs, it generated a sensitivity of 78 % and specificity of
73 %. Detailed characteristics of cutoff value of 65 ng/ml for
CAL prediction were listed in Table 2.
Discussion
The current study showed that serum levels of 25(OH)D3
were significantly higher in KD children who developed
CALs compared with children who did not develop CALs.
Higher serum 25-(OH)D3 levels in the acute phase of KD was
associated with an increased the risk of developing CALs. A
cutoff value of 65 ng/ml had a specificity of 0.73 and sensi-
tivity of 0.78 for predicting CALs. These results indicate that
25-(OH)D3 has a potential role in the pathogenesis of CALs in
children with KD.
Early identification of the risk of CALs in KD is very
important to formulate a therapeutic strategy. A well-
designed meta-analysis [3] summarized 16 biomarkers asso-
ciated with CALs in Chinese KD children. The results indi-
cated that the biomarkers, including platelet count, neutrophil
count, plateletcrit, platelet distribution width, mean platelet
volume, erythrocyte sedimentation rate, cardiac troponin I,
endothelin-1, albumin, and hemoglobin, were associated with
developing CALs among Chinese KD children. However, no
generally accepted specific biomarkers for predicting CALs in
clinical practice have been established. In addition, serum NT
pro-B-type natriuretic peptide above 1,000 pg/ml [6] or serum
sodium less than 135 mEq/l [13] has been used to diagnose
CALs secondary to KD. More recently, serum interleukin-18
was also used to identify CALs in children with KD[24].
To the best of our knowledge, the association of serum
25-(OH)D3 levels in the diagnosis of CALs among children
with KD has not been reported, and this is the first report to
identify the role of 25(OH)D3 in predicting CALs in KD. We
found that serum 25-(OH)D3 levels measured in the acute
phase KD was significantly higher in children with CALs
than those without CALs (P=0.001). A 25-(OH)D3 cutoff
point of 65 ng/ml had a sensitivity of 0.78 and specificity of
0.73 for predicting the development of subsequent CALs.
Therefore, measurement of 25-(OH)D3 levels in the acute
phase KD could be beneficial in clinical practice to identify
cardiac complications. However, 25-(OH)D3 levels were not
significantly different between the NCAL group and healthy
children, making it difficult to be used as a parameter to
exclude NCALs in KD. The mechanisms involved in the




Febrile children with respiratory
tract infections
23 27.9±20.2
Healthy control 30 44.1±30.2a
NCALs 26 49.2±23.8b
CALs 9 83.9±26.3c
Values were expressed as mean±SD
CALs coronary arterial lesions, NCALs no coronary arterial lesions
a Comparing with febrile children with respiratory tract infection group:
t=2.31 P=0.025
b Comparing with healthy control group: t=1.16, P=0.49
c Comparing with NCALs group: t=3.68, P=0.001
Fig. 1 Predictive performance of the serum 25-(OH)D3. ROCs of serum
25-(OH)D3 levels used to predict coronary arterial lesions in children
diagnosed with Kawasaki disease. The area under the curve of serum
25-(OH)D3 was 0.831
Table 2 Performance of
25-(OH)D3 with a cutoff




Positive predictive value 50
Negative predictive value 90
Diagnostic accuracy 74
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elevation of serum 25-(OH)D3 levels in the acute phase of KD
need to be explored further. The proposed mechanism include
the higher expression of VDR in T cells in KD patients than
febrile children with respiratory tract infections and healthy
children. Overactivated T cells likely promote 25-(OH)D3
release. Therefore, more intense inflammatory response in
CALs’ patients may have increased VDR expression and
subsequently elevated 25-(OH)D3 levels.
The newborn in China receive vitamin D supplement after
day 14 of birth regularly without measurement of serum
25-(OH)D level. The dosage for under 1 year old is 500 U
per day and for 1 to 2 years old is 600 U per day until 18 years
old. However, due to the vitamin D preparation available in
the market, almost all the children received vitamin D supple-
ment under 2 years old and few children more than 2 years old
received supplement vitamin D [26] .
There were some limitations in this study. The small sam-
ple size of KD children lowered the statistical power. The high
incidence of the occurrence of CALs in this study might be
correlated with the small sample size. Second, the prevalence
of CALs in the KD children directly influenced the predictive
values. Further, 25-(OH)D3 levels may vary according to race
[18] and region [21], so caution is needed before the current
results are generalized to other patients. Third, the severity of
KD is classified by the severity of coronary artery dilatation.
However, due to the small sample size, we did not conduct
correlation analysis between the severity of CALs and
25-(OH)D3 level; therefore, the relationships are still unclear
between the severity of CALs and 25-(OH)D3 level. Finally,
since 25-(OH)D3 levels were not elevated in KD children with
normal coronary arteries in the current study, serum
25-(OH)D3 levels may not be used to diagnose KD.
Conclusions
Serum 25-(OH)D3 levels greater than 65 ng/ml in the acute
phase of KD may be predictive of developing subsequent
CALs; however, it may not be helpful in the diagnosis of
KD. More studies are needed to confirm whether serum
25-(OH)D3 levels could be used to predict CALs in KD.
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